AROC CFO Sells Into the Rally as Stock Gives Back Recent Gains

Short positioning tells a much calmer story. Short interest has been falling steadily, now at 3.6% of the free float — down 11% on the week and 15% over the past month. Borrowing costs are negligible at 0.41% annually, a level that implies no conviction on the short side. Availability is exceptionally loose at nearly 2,985% of short interest, meaning the lending pool is effectively unlimited relative to current demand. The ORTEX short score of 37.5 has drifted lower all week, further confirming that short sellers are reducing rather than building positions. This is not a crowded short — it is a stock where bears are quietly retreating.

Options positioning has shifted slightly more defensive as the stock has sold off. The put/call ratio moved to 0.34, roughly one standard deviation above its 20-day average of 0.26. That is a mild uptick in hedging activity, but at 0.34 it remains historically low — the 52-week range runs all the way to 2.85 at the bearish extreme. The drift up in PCR coincides exactly with the price weakness of the past two weeks, suggesting some holders are buying downside protection rather than capitulating outright.

Analysts have not wavered. Mizuho's Gabriel Moreen raised his target to $40 from $38 just this week, maintaining an Outperform. Citigroup and Wells Fargo both lifted targets in May — to $43 apiece — while keeping Buy and Overweight ratings respectively. The consensus mean target of $41.67 implies roughly 22% upside from current levels. The bull case rests on Archrock's large-horsepower compression strategy, longer average unit tenure of over six years, and strong free cash flow. Bears point to commodity price sensitivity, the risk of oversupply in the compression market, and the potential for utilisation and pricing pressure if producer activity slows. The dividend factor score ranks in the 93rd percentile, reflecting the income appeal of the stock at these levels, though dividend history data in the dataset runs only through mid-2022 and should be verified separately. The P/E has compressed about 2.5 points over the past month to 15.8x, while EV/EBITDA has edged up slightly to 9.1x.

The next scheduled earnings release is July 31. The two most recent prints both saw the stock fall on the day — down 4.3% after the May 6 release, with a further 7.6% decline over the subsequent five days. The February result bucked that trend with a 5.1% jump and a near-10% five-day gain. With the stock already 12% lower than where insiders were selling, the July release is shaping up as a key test of whether the Street's $40-plus targets can be justified against the current price action.